<?xml version="1.0" encoding="UTF-8"?><xmi:XMI xmlns:cas="http:///uima/cas.ecore" xmlns:xmi="http://www.omg.org/XMI" xmlns:type="http:///org/apache/uima/trials/type.ecore" xmlns:tcas="http:///uima/tcas.ecore" xmi:version="2.0">
    <cas:NULL xmi:id="0"/>
    <tcas:DocumentAnnotation xmi:id="1" sofa="6" begin="0" end="1647" language="x-unspecified"/>
    <type:PFSMean xmi:id="13" sofa="6" begin="906" end="916"/>
    <type:PFSMean xmi:id="17" sofa="6" begin="936" end="946"/>
    <type:PFSMean xmi:id="29" sofa="6" begin="1307" end="1310"/>
    <type:PFSMean xmi:id="33" sofa="6" begin="1313" end="1323"/>
    <type:OSMean xmi:id="21" sofa="6" begin="1036" end="1047"/>
    <type:OSMean xmi:id="25" sofa="6" begin="1067" end="1078"/>
    <cas:Sofa xmi:id="6" sofaNum="1" sofaID="_InitialView" mimeType="text" sofaString="PURPOSE: PTK787/ZK 222584 (PTK/ZK; vatalanib), an orally active, multitargeted&#13;&#10;angiogenesis inhibitor, has shown tolerability and promising activity in&#13;&#10;early-phase studies, which led to a phase III trial in combination with&#13;&#10;oxaliplatin, fluorouracil, and leucovorin (FOLFOX4).&#13;&#10;PATIENTS AND METHODS: Patients (N = 1,168) with previously untreated metastatic&#13;&#10;colorectal cancer were randomly assigned 1:1 to receive FOLFOX4 plus PTK/ZK or&#13;&#10;placebo (ClinicalTrials.gov identifier: NCT00056459). Stratification factors&#13;&#10;included WHO performance status (0 v 1 or 2) and serum lactate dehydrogenase&#13;&#10;(LDH; = v &gt; 1.5Ã— the upper limit of normal). The primary end point was&#13;&#10;progression-free survival (PFS). Secondary end points included overall survival&#13;&#10;(OS) and overall response rate (ORR).&#13;&#10;RESULTS: PFS, OS, and ORR were not statistically improved with PTK/ZK (P &gt; .05). &#13;&#10;Median PFS by central review was 7.7 months with PTK/ZK versus 7.6 months with&#13;&#10;placebo (hazard ratio [HR], 0.88; 95% CI, 0.74 to 1.03; P = .118); median OS was &#13;&#10;21.4 months with PTK/ZK versus 20.5 months with placebo (HR, 1.08; 95% CI, 0.94&#13;&#10;to 1.24; P = .260). In an exploratory post hoc analysis of PFS in patients (n =&#13;&#10;158 per arm) with high serum LDH, a potential marker of hypoxia, PFS was longer&#13;&#10;with PTK/ZK versus placebo (7.7 v 5.8 months, respectively; HR, 0.67; 95% CI,&#13;&#10;0.49 to 0.91; P = .009).&#13;&#10;CONCLUSION: Although the efficacy objectives of this study were not met, a&#13;&#10;subgroup of patients who may potentially benefit from small-molecule vascular&#13;&#10;endothelial growth factor receptor inhibitor therapy has been identified and&#13;&#10;further research is warranted."/>
    <cas:View sofa="6" members="1 13 17 29 33 21 25"/>
</xmi:XMI>
